Abstract
There is an urgent need for effective antimicrobial agents to treat infected diabetic foot ulcers (DFUs), which are associated with debilitating symptoms, high rates of amputation, long-term disability, elevated mortality, and significant healthcare costs. This need is even more critical in the era of increasing antimicrobial resistance (AMR). Recent IWGDF/IDSA international guidelines recommend "avoiding antibiotics unless there is confirmed bacterial infection and demonstrated susceptibility to the prescribed agents."